Company profile for Retrotope

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Retrotope has created a new category of drug platform to preserve and restore mitochondrial health in degenerative diseases. The unique mechanism of Retrotope’s platform prevents cellular damage and recovers cellular function damaged by lipid peroxidation due to oxidative stress. Retrotope’s first product candidate, RT001, is being clinically tested in Friedreich’s ataxia (FA) and Infantile Neuroaxonal Dystrophy (INAD), ...
Retrotope has created a new category of drug platform to preserve and restore mitochondrial health in degenerative diseases. The unique mechanism of Retrotope’s platform prevents cellular damage and recovers cellular function damaged by lipid peroxidation due to oxidative stress. Retrotope’s first product candidate, RT001, is being clinically tested in Friedreich’s ataxia (FA) and Infantile Neuroaxonal Dystrophy (INAD), both untreated fatal orphan diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
4300 EL CAMINO REAL, SUITE 201, LOS ALTOS, CA 94022
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2021/10/19/2316320/0/en/Positive-Results-from-Studies-of-Retrotope-s-RT011-in-Animal-Models-of-Retinal-Degeneration-to-be-Featured-in-Oral-Presentations-at-2nd-Annual-Dry-AMD-Therapeutic-Development-Summi.html

GLOBENEWSWIRE
19 Oct 2021

https://www.fiercebiotech.com/biotech/retrotope-misses-main-endpoint-but-improves-survival-late-stage-trial-ultrarare-disorder

K. LaHucik FIERCEBIOTECH
07 Oct 2021

https://www.globenewswire.com/news-release/2021/10/06/2309413/0/en/Retrotope-Reports-Data-from-Phase-2-3-Clinical-Trial-of-RT001-and-Concurrent-Natural-History-Study-in-Patients-with-Infantile-Neuroaxonal-Dystrophy-INAD.html

GLOBENEWSWIRE
06 Oct 2021

https://www.clinicaltrialsarena.com/analysis/retrotope-fundraise/

CLINICAL TRIAL ARENA
30 Aug 2021

https://www.clinicaltrialsarena.com/analysis/retrotope-fundraise/

CLINICAL TRIAL ARENA
26 Aug 2021

https://www.globenewswire.com/news-release/2021/06/30/2255495/0/en/Retrotope-Announces-Initiation-of-Phase-2-Study-of-RT001-in-Patients-with-Progressive-Supranuclear-Palsy-PSP.html

GLOBENEWSWIRE
30 Jun 2021

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty